Social Media Ideas for Best In Biotech

Citi Names Top Life Science Tools & Diagnostics Stocks for Second Half

2 Biotech Stocks Worth Buying Before Their Potential Buyouts

Executive Interviews at Fierce Biotech Week 2026

Discover how these trailblazers are accelerating breakthroughs, forging impactful partnerships, and redefining what’s possible in life sciences. Access the exclusive interviews bel...

Fueled by M&A and partnerships, biotech is poised for continued growth: EY

Biotech’s effervescent activity has allowed it to overcome headwinds and sustain momentum into 2026, as the volume and value of licensing and M&A deals continues to increase. N...

The biggest biotech funding rounds in June 2026

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026. The post The biggest biotech funding rounds in Jun...

A New $21 Million Position Signals Confidence in This Post-IPO Drug Developer

This biotechnology firm leverages machine learning to design novel protein therapeutics targeting unmet medical needs.

Top biotech deals in June 2026 

June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies were forged. The post Top biotech deals in June 2026  app...

Top biotech deals in May 2026 

There were seven multibillion-dollar acquisitions that occurred in May 2026, although it was a quieter month on the biotech deals front. The post Top biotech deals in May 2026  app...

10 clinical trials to watch in the second half of 2026

The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add...

Parabilis sets a record with a $670M biotech IPO

The largest-ever new stock sale for a venture-backed biotech company extends a streak of large IPOs in 2026 that’s now resulted in 12 drug startups securing more than $4.1 billion...

‘I wouldn’t call it a blip’: Biotech IPOs here to stay after another record-breaking listing

Elon Musk's SpaceX may be igniting global headlines with the company's astronomical IPO, but biotech listings saw their own record-breaker this week.

<![CDATA[Biogen Enters $1 Billion Agreement to Acquire RayThera Inc. ]]>

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable

11 biotech companies leading the way in Denmark

Explore Denmark's dynamic biotech scene with 10 innovative companies at the forefront of the biopharmaceutical revolution! The post 11 biotech companies leading the way in Denmark...

StockWatch: Parabilis Medicines Makes Wall Street History with $770.5M IPO

Parabilis’ IPO surpasses the $625 million IPO carried out in April by Kailera Therapeutics, which topped the previous record-high among U.S. biotechs, the $604 million offering of...

These biotechs just landed big fundraising hauls. Here’s what they pitched to investors.

Biotechs aimed at eye diseases, autoimmune conditions and longevity medicine have pulled in some of the largest capital raises so far this year.

‘The window’s open’: At BIO, investors take stock of a growing class of biotech IPOs

In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in offerings later this year — but only among companies fitt...

The biggest biotech funding rounds in May 2026

Isomorphic Labs, Apogee Therapeutics, and Avalo Therapeutics bagged the biggest biotech funding rounds overall in May 2026. The post The biggest biotech funding rounds in May 2026...

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

Taiwan's biopharma sector steps into spotlight with rush of IPOs

India's biotech push reaches an inflection point, but funding remains the missing piece

Historically, Indian pharmaceutical companies have focused on generics and services businesses, which carry lower risk and shorter development

Biotech value creation at an inflection point

Capital is tighter and expectations are higher. Hear how biotech leaders must rethink value, evidence and deal readiness in 2026.

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.